SK-LMS-1 cell

SK-LMS-1 is a human leiomyosarcoma cell line that has been widely used for cancer research, particularly for studies investigating therapeutic agents targeting soft tissue sarcomas. Leiomyosarcoma is a type of malignant tumor that arises from smooth muscle tissues, and the SK-LMS-1 cell line models this disease effectively in vitro. These cells express the c-Met proto-oncogene, which plays a critical role in tumorigenesis, proliferation, and metastasis in many cancers, including leiomyosarcoma. The aberrant expression of c-Met in SK-LMS-1 makes it a valuable model for studying c-Met-targeted therapies. One significant study involved the identification of a Met-binding peptide, Met-pep1, through phage display library screening. This peptide demonstrated specificity for the Met receptor and was capable of competing with hepatocyte growth factor (HGF) for receptor binding, inhibiting tumor cell proliferation. SK-LMS-1 cells treated with Met-pep1 showed decreased proliferation, suggesting that targeting c-Met with this peptide could have therapeutic potential. The internalization of the peptide by SK-LMS-1 cells after binding to c-Met further supports its potential as a diagnostic or therapeutic agent, particularly in nuclear imaging studies where tumor-associated activity was successfully visualized in vivo using SK-LMS-1 xenografts. Additionally, SK-LMS-1 cells have been used to explore the effects of natural compounds such as Flavokawain B (FKB), a chalcone derived from the kava plant. FKB was found to induce G2/M cell cycle arrest and robust apoptosis in SK-LMS-1 cells, mediated by the upregulation of pro-apoptotic proteins like DR5, Bim, and Puma, and downregulation of the anti-apoptotic protein survivin. The combination of FKB with chemotherapeutic agents such as docetaxel and gemcitabine exhibited a synergistic effect, further inhibiting the growth of SK-LMS-1 cells.

SKU:BHC11100704

• SDS (530D46EA30D448588B4B4B1BEAF8F2CB)
• Product Sheet (530D46EA30D448588B4B4B1BEAF8F2CB)
• SK-LMS-1 300125-719 Cytion CoA (PDF)

• Antigen expression: Blood Type O, Rh+
• Isoenzymes: Me-2, 2, PGM3, 1-2, PGM1, 1-2, ES-D, 1, AK-1, 1, GLO-1, 1-2, G6PD, B, Phenotype Frequency Product: 0.0027
• Tumorigenic: Yes, in nude mice. Forms leiomyosarcoma
• Karyotype: (P12) hypotriploid to hypertriploid (+A2, +A3, +C, +D, +E, +F, +G, -A) with abnormalities including dicentrics, acrocentric fragments, breaks, secondary constrictions, minutes and large submetacentric markers

• cultureMedium: DMEM:Ham's F12 (1:1), w: 3.1 g/L Glucose, w: 2.5 mM L-Glutamine, w: 15 mM HEPES, w: 0.5 mM Sodium pyruvate, w: 1.2 g/L NaHCO3 (Cytion article number 820400a)
• supplements: Supplement the medium with 10% FBS
• dissociationReagent: Accutase
• subculturing: Remove the old medium from the adherent cells and wash them with PBS that lacks calcium and magnesium. For T25 flasks, use 3-5 ml of PBS, and for T75 flasks, use 5-10 ml. Then, cover the cells completely with Accutase, using 1-2 ml for T25 flasks and 2.5 ml for T75 flasks. Let the cells incubate at room temperature for 8-10 minutes to detach them. After incubation, gently mix the cells with 10 ml of medium to resuspend them, then centrifuge at 300xg for 3 minutes. Discard the supernatant, resuspend the cells in fresh medium, and transfer them into new flasks that already contain fresh medium.
• fluidRenewal: 2 to 3 times per week
• freezeMedium: As a cryopreservation medium, use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability, or CM-1 (Cytion catalog number 800100), which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress.